Roche's Avastin boosts survival of brain cancer patients
ZURICH Aug 10 (Reuters) - Swiss drugmaker Roche Holding AG said a new study of cancer drug Avastin showed it significantly extended life expectancy of people with an aggressive form of brain cancer.
The Phase III AVAglio study met one of its main targets of improving progression-free survival in people with glioblastoma, Roche, the world's largest maker of cancer drugs, said in a statement on Friday.
"This study showed that people with glioblastoma, a particularly devastating and aggressive cancer without many treatment options, lived significantly longer without their disease worsening when Avastin was added to radiation and temozolomide chemotherapy," Roche said.
(Reporting by Andrew Thompson)
- Tweet this
- Share this
- Digg this
- Bangalore-bound Malaysian plane lands safely after landing gear scare
- Calls to U.S. poison centers involving e-cigarettes jump - CDC
- India passes halfway mark in election with BJP gaining strength
- UPDATE 1-Saudi Arabia announces jump in new cases of deadly MERS virus
- Mercedes, BMW chase ultra rich clients with new high end cars